Case File
efta-02566466DOJ Data Set 11OtherEFTA02566466
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02566466
Pages
8
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Barrett, Paul S <
Sent:
Thursday, February 14, 2013 6:30 PM
To:
Epstein, Jeffrey ([email protected])
Cc:
Weissend, Renee E; Ens, Amanda
Subject:
NEW HY RMBS - $12.98mm of SARM 040-4 B1 @ $59-16 (7.24% yield/ 7.55 durn)
Jeffrey
We should buy 51MM of this for Jeepers.
Paul
*** ALL OFFERS ARE SUBJECT
US Onshore Clients — Blue Sky (U.S. State Securities Law): Please confirm Blue Sky eligibility before soliciting to a US
Onshore client by entering the CUSIP into the web tool located at:
http://pscppvl.amer.jpmchase.net:8080/BlueSkyPage.html and review to see if your client's state of residence is listed.
If you receive 'NO SECURITY FOUND', 'NO STATES FOUND' or the security DOES NOT HAVE A CUSIP or is not USD-
denominated, then please contact your SM or local compliance officer and provide the requested security and client
information. Please note that a suitability review and other pre-trade procedures must still be followed.
THE BOND:
The SARM 04-4 Ei1 is an Alt-A Seasoned Hybrid Sub bond backed by 107 months seasoned Hybrid ARM mortgages. The
bond has 3.15% credit enhancement vs 12.99% 60+ delinquencies, for a 0.24x coverage ratio.
THE COLLATERAL:
The pool consists of 773 Alt-A loans that are 107 months seasoned with an average updated LTV of 69%. 71% of the
borrowers have not missed a payment in the past 2 years. The average 6 month CDR and severity has been 2.28% and
36%, respectively. Our base case assumes 2.5% CDR ramping up to 6% CDR over 2 years and a 40% severity ramping
down over 2years to 35%. At these assumptions, we are defaulting 18% of the pool when only 13% is in 60+
delinquency and project a 7.24% yield @ 559-16.
THE STORY:
For investors looking for a housing recovery play backed by seasoned collateral, this bond offers a great convexity story
levered to prepayments and overall homeowner performance.
Please call the desk with all bids/inquiries related to this bond. X32124
HIGHLIGHTS
EFTA_R1_01731677
EFTA02566466
HPI Updated LTV = 69%
71% of the borrowers have not missed a payment in the past 2 years
107 months seasoned
715 FICO
$296k average balance
"Source: Bloomberg
SARM 2004-4 B1 Offered @ 59-16
BOND DESCRIPTION
Prepay Rate
4 CPR
8 CPR
10 CPR
Cusip:
86359BPE5
Default Rate
3 ramp 24 7 7 ramp 12 2 CDR
2.5 ramp 2466 ramp 122 CDR
2.5 ramp 2466 ramp 122 CDR
Original Face:
12,976,407
Default Severity
45 ramp 36 40
40 ramp 24 35
2
EFTA_R1_01731678
EFTA02566467
40 ramp 18 35
Current Face:
6,718,757
Delinq Rate
13 Percent
13 Percent
13 Percent
Bond Type:
Alt-A Hybrid Sub
Delinq Advance (% of P&I)
85
95
100
Ratings (S&P/Moodys/Fitch):
CCC/-/-
Call
No
No
No
Current Coupon:
2.899%
Yield @ Base Case
7.241%
Price @ 59-16
Stress Case
Base Case
3
EFTA_R1_01731679
EFTA02566468
Recovery Case
WAL @ Base Case
9.93
Yield
1.864
7.241
7.920
Principal Window @ Base Case
Mar13 to Sep47
Spread over Tsy
25
514
581
Writedown %
31.89%
Duration
7.52
7.55
7.42
Current Credit Enhancement:
3.15%
WAL
7.31
9.93
9.99
60+ Delinquencies
4
EFTA_R1_01731680
EFTA02566469
12.99
Principal Window
Mar13 to Aug46
Mar13 to Sep47
Mar13 to Sep47
60+ Delinquency Coverage
0.24x
Principal Writedown
61.68%
31.89%
26.50%
Total Collat Loss
2.71%
2.13%
2.03%
UNDERLYING COLLATERAL DESCRIPTION
Total Liquidation
23.10%
17.88%
16.41%
Average Loan Balance ($,000s)
296
Loan Count
773
HISTORICAL PERFORMANCE
5
EFTA_R1_01731681
EFTA02566470
Mortgage Type
Alt-A Hybrid ARMs
1 MOS
3 MOS
6 MOS
Wtd Avg Mortgage Coupon
3.169%
CPR
9.36
10.04
8.97
Wtd Avg FICO Score
715
CDR
3.43
1.86
2.28
Wtd Avg Orig Loan-to-Value
67.20%
SEV
37.02
43.01
6
EFTA_R1_01731682
EFTA02566471
36.28
HPI Adj LTV
68.75%
Weighted Avg Loan Age
107
Owner Occupied
69.07
Top 1 Geo Concentration
CA 44%
Top 2 Geo Concentration
CO 10%
Top 3 Geo Concentration
FL 5%
Always Current (24 mos)
70.79%
IMPORTANT DISCLAIMER:
Non-agency RM85 is a complex fixed income product and is not suitable for all investors. Please note that while desk
assumptions are driven by a number of collateral and macro factors, the historical performance of a deal is not
indicative of its future performance. Additionally, this message is a product of sales and trading and is not a research
report. Other key risks to consider are outlined below:
All investments are subject to possible loss of principal
7
EFTA_R1_01731683
EFTA02566472
Non-Agency bonds may have limited liquidity and clients should be aware that the secondary market for
mortgage-backed securities has experienced periods of illiquidity and may do so in the future. Illiquidity means that
there may not be any purchasers for your class of certificates. Although any class of certificates may experience
illiquidity, it is more likely that classes that are lower in the capital structure and non-investment grade related may
experience greater illiquidity than more senior, investment-grade rated classes.
High Yield Non-Agency bonds are speculative non-investment grade bonds that have higher risk of default or
other adverse credit events which are appropriate for high risk investors only
Non-Agency bonds are intended for clients with a minimum total net worth of $50mm. Please make sure your client
fulfills this requirement before soliciting this order.
This commentary is a product of JPMorgan Global Wealth Managements Taxable Fixed Income Trading Desk and not
JPMorgan's Research Department. The views expressed in this trading desk commentary may differ from those of
JPMorgan's Research Department. Any opinions expressed in this trading desk commentary are subject to change
without notice and JPMorgan is under no obligation to update or keep this information current.
Bee-Ann Benson I Vice President I J.P. Morgan Global Wealth Management
270 Park Avenue, Floor 5, New York, New York 10017
This email is confidential and subject to important disclaimers and conditions including on offers for the purchase or sale
of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and legal entity
disclaimers, available at http://www.jpmorgan.com/pages/disclosures/email.
8
EFTA_R1_01731684
EFTA02566473
Technical Artifacts (11)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Phone
2566466Phone
2566467Phone
2566468Phone
2566469Phone
2566470Phone
2566471Phone
2566472Phone
2566473URL
http://pscppvl.amer.jpmchase.net:8080/BlueSkyPage.htmlURL
http://www.jpmorgan.com/pages/disclosures/emailRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.